Sugi Predict

Sugi Predict / Compounds / SCHEMBL1358844

SCHEMBL1358844

SCHEMBL1358844

O=[N+]([O-])c1c(F)cc(Br)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ ERN1 O75460 1/20 0.36
▸ GRIN2D O15399 3/20 0.36
▸ GRIN3B O60391 3/20 0.36
▸ GRIN1 Q05586 3/20 0.36
▸ GRIN2A Q12879 3/20 0.36
▸ GRIN2B Q13224 3/20 0.36
▸ GRIN2C Q14957 3/20 0.36
▸ GRIN3A Q8TCU5 3/20 0.36
▸ MAPT P10636 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ VCAM1 P19320 1/20 0.35
▸ VCP P55072 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ S100A4 P26447 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14246396 0.89 MAPT (0.40) TDP1ATMALDH1A1TSHRHIF1A
SCHEMBL1192809 0.87 GRIN2D (0.39) TDP1ATMALDH1A1TSHRHIF1A
SCHEMBL18398583 0.86 ERN1 (0.39) TDP1ATMALDH1A1TSHRHIF1A
SCHEMBL14247122 0.86 ALDH1A1 (0.50) TDP1ATMALDH1A1TSHRHIF1A
SCHEMBL30487407 0.86 TDP1 (0.41) TDP1ATMALDH1A1TSHRGRIN2D
SCHEMBL31159817 0.86 ERN1 (0.39) TDP1ATMALDH1A1TSHRHIF1A
SCHEMBL9000071 0.86 TDP1 (0.41) TDP1ATMALDH1A1TSHRGRIN2D
SCHEMBL26339899 0.82 GRIN2D (0.41) TDP1ATMALDH1A1HIF1AGRIN2D
SCHEMBL25252333 0.81 GPR35 (0.41) TDP1ALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL1675629 0.81 MAPT (0.43) TDP1ALDH1A1ERN1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117417867-A Enterobacter cloacae (Enterobacter cloacae) ZJUT16 and application thereof 浙江工业大学 2024-01-19 — — CN claimed
CN-117343948-A Recombinant expression plasmid of nitroreductase EcNTR and application thereof 浙江工业大学 2024-01-05 — — CN claimed
WO-2026107422-A1 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE BRISTOL-MYERS SQUIBB COMPANY (US) 2026-05-21 — — WO disclosed
EP-4743447-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF CANCER AND METABOLIC DISEASES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2026-05-20 — — EP disclosed
CN-122059906-A Compounds for inhibiting PTPN proteins and uses thereof 艾斯拓康生物医药(天津)有限公司 2026-05-19 — — CN disclosed
CN-122036690-A Heteroaromatic ring compound, pharmaceutical composition and application thereof 马应龙药业集团股份有限公司 2026-05-15 — — CN disclosed
CN-122010871-A Compounds for inhibiting PTPN proteins and uses thereof 艾斯拓康生物医药(天津)有限公司 2026-05-12 — — CN disclosed
US-12622905-B2 Aryl pladienolides for the treatment of neoplastic disorders EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-05-12 — — US disclosed
WO-2026087650-A1 VINYLOXY-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER SANOFI (FR) 2026-04-30 — — WO disclosed
WO-2026087651-A1 CYCLOPROPANE-ARYL COMPOUNDS FOR THE TREATMENT OF CANCER SANOFI (FR) 2026-04-30 — — WO disclosed
EP-4720057-A2 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2026-04-08 — — EP disclosed
WO-2007036715-A2 COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-04-05 — — WO disclosed
US-20060122196-A9 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2006-06-08 — — US disclosed
WO-2006022773-A1 GYRASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-02 — — WO disclosed
US-20060025424-A1 Gyrase inhibitors and uses thereof CHARIFSON PAUL 2006-02-02 — — US disclosed
US-20050256136-A1 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-11-17 — — US disclosed
EP-1592686-A1 GYRASE INHIBITORS AND USES THEREOF Vertex Pharmaceuticals Incorporated (US) 2005-11-09 — — EP disclosed
US-20050038247-A1 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2005-02-17 — — US disclosed
WO-2005012292-A1 GYRASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-02-10 — — WO disclosed
US-20040235886-A1 Gyrase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122196-A9 Gyrase inhibitors and uses thereof TOP1, TOP2A, TOP2B TDP1 27/4885ATM 1319/4885ALDH1A1 3787/4885
US-12622905-B2 Aryl pladienolides for the treatment of neoplastic disorders SF3B1, SF3B5, SF3B2 TDP1 987/4885ATM 4000/4885ALDH1A1 2099/4885
US-20040235886-A1 Gyrase inhibitors and uses thereof TOP1, TOP2A, TOP2B TDP1 28/4885ATM 1323/4885ALDH1A1 3801/4885
US-20060025424-A1 Gyrase inhibitors and uses thereof TOP1, TOP2A, TOP2B TDP1 27/4885ATM 1319/4885ALDH1A1 3787/4885
US-20050256136-A1 Gyrase inhibitors and uses thereof TOP1, TOP2A, NQO2 TDP1 36/4885ATM 2031/4885ALDH1A1 1650/4885
US-20050038247-A1 Gyrase inhibitors and uses thereof TOP1, TOP2A, TOP2B TDP1 27/4885ATM 1319/4885ALDH1A1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.